Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | BCR | P11274 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385788 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL672403 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL9138875 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL29519283 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL3649190 | 0.85 | CYP19A1 (0.46) | ALDH1A1CYP2D6POLBMAPTCYP3A4 | |
| SCHEMBL1117240 | 0.84 | TSHR (0.50) | ALDH1A1POLBSMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL278730 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL279049 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL15286114 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP2D6POLBSMN1; SMN2MAPT | |
| SCHEMBL6208751 | 0.83 | TSHR (0.49) | ALDH1A1CYP2D6POLBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025215153-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2025-10-16 | — | — | WO | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2025108255-A1 | POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025001408-A1 | PHOSPHORUS-CONTAINING OR SULFUR-CONTAINING MACROCYCLIC PYRAZOLOPYRIMIDINE COMPOUND AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2025-01-02 | — | — | WO | disclosed |
| WO-2024240894-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| CN-116262739-A | Nitrogen-containing aryl derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| EP-2049107-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | Genfit (FR) | 2009-04-22 | — | — | EP | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885CYP2D6 46/4885POLB 1031/4885 |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | ALDH1A1 2437/4885CYP2D6 403/4885POLB 1088/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885CYP2D6 46/4885POLB 1031/4885 |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | ALDH1A1 464/4885CYP2D6 621/4885POLB 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.